相似文献
1
What have we learnt from Vioxx?
BMJ. 2007 Jan 20;334(7585):120-3. doi: 10.1136/bmj.39024.487720.68.
2
Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
BMJ. 2009 Apr 6;338:b1432. doi: 10.1136/bmj.b1432.
3
4
Open conflict on the handling of the Merck drug Vioxx by editorial giants.
Reprod Biomed Online. 2006 Dec;13(6):905. doi: 10.1016/s1472-6483(10)61040-1.
5
A message from the Vioxx case.
Am J Health Syst Pharm. 2006 Mar 15;63(6):503. doi: 10.2146/ajhp050427.
6
Quebec allows Vioxx class-action suit.
CMAJ. 2007 Jan 2;176(1):20. doi: 10.1503/cmaj.061600.
7
The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1.
J Law Med. 2010 Sep;18(1):38-49.
8
Merck's Careful Study of Vioxx.
Am J Cardiol. 2008 Apr 1;101(7):1068-9; author reply 1069. doi: 10.1016/j.amjcard.2007.10.042.
9
The preacher who's raising hell with Merck.
Fortune. 2005 Aug 8;152(3):20.
10
The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
J Anesth. 2006;20(4):348-51. doi: 10.1007/s00540-006-0432-7.
引用本文的文献
1
Photoaffinity Ligand of Cystic Fibrosis Corrector VX-445 Identifies SCCPDH as an Off-Target.
ACS Chem Biol. 2025 Jul 18;20(7):1560-1573. doi: 10.1021/acschembio.5c00157. Epub 2025 Jun 20.
2
A Review of the Applications, Benefits, and Challenges of Generative AI for Sustainable Toxicology.
Curr Res Toxicol. 2025 Apr 21;8:100232. doi: 10.1016/j.crtox.2025.100232. eCollection 2025.
3
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies.
Drugs. 2025 Apr;85(4):505-555. doi: 10.1007/s40265-025-02162-4. Epub 2025 Mar 17.
4
Political economics in health and implications for neurosurgery diseases.
Front Public Health. 2025 Jan 28;12:1444249. doi: 10.3389/fpubh.2024.1444249. eCollection 2024.
5
Lest a Smoky Haze of Doubt Suffocate Progress toward Better Pulse Oximeters.
Ann Am Thorac Soc. 2025 Mar;22(3):322-324. doi: 10.1513/AnnalsATS.202411-1213ED.
6
NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead.
RSC Adv. 2024 Sep 25;14(42):30647-30661. doi: 10.1039/d4ra04686b. eCollection 2024 Sep 24.
7
Methods for assessing inverse publication bias of adverse events.
Contemp Clin Trials. 2024 Oct;145:107646. doi: 10.1016/j.cct.2024.107646. Epub 2024 Jul 30.
8
Reporting Compliance and Factors Influencing Timeliness of Stroke-Related Trial Results on ClinicalTrials.gov.
Transl Stroke Res. 2025 Jun;16(3):775-780. doi: 10.1007/s12975-024-01260-x. Epub 2024 Jun 3.
9
Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses.
Viruses. 2024 Apr 22;16(4):647. doi: 10.3390/v16040647.
10
Disclosing and Managing Non-Financial Conflicts of Interest in Scientific Publications.
Res Ethics. 2023 Apr;19(2):121-138. doi: 10.1177/17470161221148387. Epub 2023 Jan 12.
本文引用的文献
1
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet. 2006 Nov 18;368(9549):1771-81. doi: 10.1016/S0140-6736(06)69666-9.
2
Despite warnings, drug giant took long path to Vioxx recall.
N Y Times Web. 2004 Nov 14:A1, A32.
Zotero 插件